StockNews.AI
URGN
StockNews.AI
68 days

Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact The Gross Law Firm about pending Class Action - URGN

1. UroGen Pharma facing class action regarding misleading statements about UGN-102. 2. Allegations cite flaws in ENVISION study design affecting drug approval chances. 3. Shareholders encouraged to register for potential lead plaintiff status. 4. Class period spans until May 15, 2025, impacting investor sentiment. 5. Gross Law Firm emphasizes commitment to safeguarding shareholder rights.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of misleading information regarding UGN-102 could deter investors, as similar past cases have caused significant share price drops for companies like Valeant Pharmaceuticals during their scandals. The risk of NDA rejection means potential future earnings and stock performance are in jeopardy.

How important is it?

The substantial risks associated with the allegations can lead to significant investor fallout, making this highly pertinent to URGN's current and future stock performance. Similar lawsuits in biotech sectors have historically led to sharp declines in stock values.

Why Long Term?

Long-term effects are expected if the allegations lead to a negative ruling or prolonged uncertainty around UGN-102's approval, influencing stock volatility much like earlier cases in the sector.

Related Companies

NOTICE TO SHAREHOLDERS OF UROGEN PHARMA LTD.

NEW YORK, June 12, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).

Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/urogen-pharma-ltd-loss-submission-form/?id=152580&from=4

CLASS PERIOD:

July 27, 2023 to May 15, 2025

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company's lead pipeline product, UGN-102, because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA's warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE:

July 28, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/urogen-pharma-ltd-loss-submission-form/?id=152580&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of URGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 28, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm

Related News